· Periodic Report
Q3 profit from the main business KRW 8.2 billion, down 23.0% from a year earlier
Daehan Pharm sold KRW 57.0 billion in Q3 and earned KRW 8.2 billion from its main business, down 23.0% from a year earlier and up 1.4% from the prior quarter.